Salute e Benessere

CORRECTION: Orion Corporation: Managers' transactions – EVK-Capital Oy

ORION CORPORATIONMANAGERS' TRANSACTIONS1 JUNE 2023 at 21.00 EEST CORRECTION: Orion Corporation: Managers' transactions – EVK-Capital Oy Correction to the stock exchange release published on 1 June 2023 at 18.45 EEST regarding managers' transactions. In the original notification, the person subject to the notification requirement was incorrectly Eija Ronkainen. The correct person subject to the notification requirement is EVK-Capital Oy. Below is the information in the...
Nasdaq GlobeNewswire
01/06/2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – June 1 , 2023 – 7 .00 PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on May 26, 2023, from...
Nasdaq GlobeNewswire
01/06/2023

Operating Room Integration Market worth $3.7 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667 Browse in-depth TOC on "Operating Room Integration Market" 133 - Tables 33 - Figures 192 - Pages Operating Room Integration Market Scope: Software segment accounted for the largest share of the operating room integration market, By Technology The software segment...
PR Newswire
01/06/2023

Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board /…

Press release Dijon, 1 stJune 2023, 6.30 p.m. Appointment of Daniel Teper to the Crossject Supervisory BoardBuilding skills to support the US transition CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations(epilepsy, allergic shock, overdose, asthma attack, adrenal insufficiency, etc.), has decided to submit Daniel Teper's appointment as a Director on its...
Nasdaq GlobeNewswire
01/06/2023

Monthly Publication of the Number of Shares Composing the Share Capital and of…

Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On June 1, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlementgénéral of the l'AMF) As of May 31, 2023 Total number of shares...
Nasdaq GlobeNewswire
01/06/2023

AB Science announces issuance of a Canadian patent for masitinib in the…

PRESS RELEASEAB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)WITH PROTECTION UNTIL 2037CANADIAN PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR ALS ACROSS ALL KEY GEOGRAPHIC AREAS WHERE MASITINIB COULD BE MARKETED, INCLUDING EUROPE, USA , CHINA, JAPAN AND SOUTH KOREAParis, 1stJune , 2023 ,6pm CETAB Science SA(Euronext - FR0010557264 - AB) today...
Nasdaq GlobeNewswire
01/06/2023

Booming UAE Construction Equipment Market Set to Scale New Heights, Anticipates…

Increased investment in renewable energy projects to boost the demand for material handling equipment. In 2021, the UAE revealed its Net Zero 2050 Strategy Initiative, with a value of $163.3 billion, which aims to invest in clean and renewable energy resources over the next three decades. According to the 2022 data, the UAE plans to invest $160 billion in developing renewable energy projects nationwide. Increased investment in renewable energy projects to boost the demand for material handling…
PR Newswire
01/06/2023

Orion Corporation: Managers' transactions – Eija Ronkainen

ORION CORPORATIONMANAGERS' TRANSACTIONS1 JUNE 2023 at 18.45 EEST Orion Corporation: Managers' transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
01/06/2023

Hygienic Pumps and Valves Market worth $2.8 billion by 2028 - Exclusive Report…

Browse in-depth TOC on "Hygienic Pumps and Valves Market" 163 – Tables70 – Figures232 – Pages Browse in-depth TOC on "Hygienic Pumps and Valves Market" 163 – Tables 70 – Figures 232 – Pages Hygienic Pumps and Valves Market Report Scope: The market for the control valves segment is expected to grow at the highest CAGR during the forecast period. Control valves automatically regulate essential process variables such as temperature, direction, level, pressure, and flow rate…
PR Newswire
01/06/2023

Idiopathic Membranous Nephropathy Market to Register Immense Growth at a CAGR of…

Key Takeaways from the Idiopathic Membranous Nephropathy Market Report Key Takeaways from the Idiopathic Membranous Nephropathy Market Report Discover which therapies are expected to grab the major idiopathic membranous nephropathy market share @Idiopathic Membranous Nephropathy Market Report Idiopathic Membranous Nephropathy Overview Membranous nephropathy is a kidney disease affecting the kidney's filters. It causes a rise in protein in the urine, impaired renal function,...
PR Newswire
01/06/2023

The Bispecific Antibodies Market is projected to grow at a CAGR of 9.5% till…

Having demonstrated the ability to selectively target various antigens responsible for the development of oncological and non-oncological disorders, a number of bispecific antibodies have so far been evaluated and approved for the treatment of such indications, including the most recent approval of Tecvayli™ in October 2022 for the treatment of multiple myeloma. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the bispecific…
PR Newswire
01/06/2023

Household Cleaners Market to Reach $53.3 Billion, Globally, by 2031 at 4.6%…

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/7173 Download Free Sample Report:https://www.alliedmarketresearch.com/request-sample/7173 Prime determinants of growth The global household cleaners market is experiencing growth due to factors such as rise in demand for household cleaners, increase in the number of households, and the requirement of cleaning products in households to maintain a clean and healthy environment. On the other hand,...
PR Newswire
01/06/2023

Infrared Imaging Market Zooms Towards Billion-Dollar Valuation: Estimated to…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=6013 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=6013 Browse in-depth TOCon" Infrared Imaging Market " 202 - Pages 126 – Tables 37 – Figures Infrared Imaging Technology Drives Advancements in Disease Detection and Surgical Applications Infrared imaging, a non-invasive technique utilizing infrared radiation for disease detection, is revolutionizing...
PR Newswire
01/06/2023

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team…

"The encouraging clinical results we are seeing with our three internally owned drug programs, and our plan to rapidly expand our clinical footprint over the next several years, are leading us to double the size of our clinical team in 2023," said Bill Haney, Dragonfly's CEO and co-founder. "Robin and David, who will run Translational Medicine and Clinical Development in Oncology, respectively, are fantastic additions to the Dragonfly team." "The encouraging clinical…
PR Newswire
01/06/2023

AtomVie Global Radiopharma raises over $90M to Complete its New Facility…

"Avego is pleased to expand its partnership with AtomVie, a collaboration that underscores our commitment to growth and innovation. AtomVie's new facility, set to open in late 2024, will handle meaningful clinical and commercial programs with advance booking of manufacturing capacity available today" said Kevin McNeill, Partner at Avego. "Avego is pleased to expand its partnership with AtomVie, a collaboration that underscores our commitment to growth and innovation. AtomVie's new…
PR Newswire
01/06/2023

H.Spectrum+ Funding Bold New Ideas Worldwide for Disruption in Health Tech

To submit an innovative idea or learn more, please visit: https://docs.google.com/forms/d/e/1FAIpQLSeefgf6_W-FlD3lkfomPXZkfl4JvJi1ZnVJndnhSbMYAPsgcQ/viewform To submit an innovative idea or learn more, please visit: https://docs.google.com/forms/d/e/1FAIpQLSeefgf6_W-FlD3lkfomPXZkfl4JvJi1ZnVJndnhSbMYAPsgcQ/viewform In the wake of the collapse of Silicon Valley Bank, whichthe life sciences and healthcare industries relied on heavily, a gap in funding opportunities has left health tech...
PR Newswire
01/06/2023

Philips and Masimo introduce new, advanced monitoring capabilities to Philips…

Amsterdam, the Netherlands and Irvine, California, U.S. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Masimo (NASDAQ: MASI), a global medical technology company, today announced FDA clearance allowing the activation of SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO 2measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension of Masimo and Philips' ongoing collaboration will help enable...
Nasdaq GlobeNewswire
01/06/2023

Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of…

Another report from Maximize Market Research projects that the Neurofibromatosis Treatment Market value is projected to reach US$ 27.06 Bn at the end of the forecast period (2029) and it is expected to grow at the CAGR of 13.3%. The report. Added: "Ongoing development of novel therapies for treating neurofibromatosis drives the market growth. Increasing R&D activities and focus of major players for the development of novel therapies for treatment is expected to drive the market. Also…
PR Newswire
01/06/2023

Aravax doses first patient in Phase 2 peanut allergy clinical trials

In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed. In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed. "We're thrilled to have dosed our first patient in Phase 2. In this Phase 2 trial we will evaluate how the immunological changes observed in Phase…
PR Newswire
01/06/2023

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of…

SAN FRANCISCO and BERLIN, June01, 2023(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced presentation of a poster titled, “MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to...
Nasdaq GlobeNewswire
01/06/2023

Amolyt Pharma Launches Public Awareness Campaign to Honor World…

Amolyt Pharma's public awareness campaign is centered on the artistic representation of living with hypoparathyroidism, a rare endocrine disease that has remained unnoticed despite the debilitating symptoms and poor quality of life experienced by patients. Discussions between artists and patients in the U.S. and in France led to the creation of two pieces of artwork that express how patients affected by hypoparathyroidism cope with the disease.The artwork was unveiled during an event in...
Nasdaq GlobeNewswire
01/06/2023

'All United for MG' organises first-ever European Myasthenia Gravis Day on June…

"Raising awareness about myasthenia gravis is not just about spreading knowledge, it's about empowering those who are living with it. It's about fostering compassion and understanding amongst the general public to improve healthcare, break down stigmas, and ultimately create a world where people with MG can thrive. Our aim is to enhance patients' quality of life and reduce their mental burden," conclude the founders of the European Myasthenia Gravis Day. "Raising awareness about…
PR Newswire
01/06/2023

Eliassen Group Appoints New Life Sciences Executive Leadership to Fuel…

Brandon is a collaborative sales executive with over 20 years of life science industry experience who has displayed consistent success in driving sales and go-to-market strategies in both the clinical and commercial arenas. Brandon has held various leadership roles in his career on both the CRO and sponsor sides, and he has also been involved in the launch of a number of key pharmaceutical products across various therapeutic areas, disease states, markets, and healthcare settings. At Eliassen…
PR Newswire
01/06/2023

Seegene Obtains IVDR Certification for 30 Diagnostic Assays

The IVDR was established to raise quality standards and ensure that existing European In Vitro Diagnostic Medical Device Directive (IVDD) devices are safe. Seegene has proactively responded to recent regulatory changes and secured the mandatory certification. All manufacturers of in vitro diagnostic devices, such as PCR diagnostic assays, must obtain IVDR certification before selling these medical devices in the European market. The IVDR was established to raise quality standards and ensure...
PR Newswire
01/06/2023
Altri  Comunicati